Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MYOSITIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL MYOSITIS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR XX
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL MYOSITIS TREATMENT MARKET, BY TYPE
14.1 OVERVIEW
14.2 INCLUSION BODY MYOSITIS (IBM)
14.2.1 SPORADIC INCLUSION BODY MYOSITIS (S-IBM)
14.2.2 HEREDITARY INCLUSION BODY MYOPATHY (H-IBM)
14.3 DERMATOMYOSITIS
14.3.1 DERMATOMYOSITIS SINE MYOSITIS
14.3.2 ADULTY DERMATOMYOSITIS
14.3.3 JUVENILE DERMATOMYOSITIS
14.4 POLYMYOSITIS
14.5 NECROTIZING MYOPATHY
14.6 JUVENILE MYOSITIS
14.7 OTHERS
15 GLOBAL MYOSITIS TREATMENT MARKET, BY TREATMENT
15.1 OVERVIEW
15.2 MEDICATION
15.2.1 CORTICOSTEROIDS
15.2.1.1. PREDNISONE
15.2.1.2. METHYLPREDNISOLONE
15.2.1.3. PREDNISOLONE
15.2.1.4. ACTHAR (ADRENOCORTICOTROPIC HORMONE, ACTH)
15.2.1.5. OTHERS
15.2.2 IMMUNOSUPPRESSANTS
15.2.2.1. AZATHIOPRINE
15.2.2.2. METHOTREXATE
15.2.2.3. CYCLOSPORINE
15.2.2.4. CYCLOPHOSPHAMIDE
15.2.2.5. MYCOPHENOLATE MOFETIL
15.2.2.6. TACROLIMUS
15.2.2.7. HYDROXYCHLOROQUINE
15.2.2.8. OTHERS
15.2.3 IMMUNOGLOBULINS
15.2.3.1. IMMUNE GLOBULINS INTRAVENOUS
15.2.3.2. IMMUNE GLOBULINS SUBCUTANEOUS
15.2.3.3. OTHERS
15.2.4 MONOCLONAL ANTIBODIES
15.2.5 ALKYLATING AGENTS
15.2.6 OTHERS
15.3 SUPPLEMENTS
15.3.1 CREATINE MONOHYDRATE
15.3.2 MITOCHONDRIAL COCKTAIL
15.3.3 OTHERS
15.4 THERAPY
15.4.1 PHYSICAL THERAPY
15.4.2 OCCUPATIONAL THERAPY
15.4.3 SPEECH THERAPY
15.4.4 SELF-CARE THERAPY
15.4.5 OTHERS
16 GLOBAL MYOSITIS TREATMENT MARKET, BY DIAGNOSIS
16.1 OVERVIEW
16.2 MUSCLE BIOPSY
16.3 ELECTROCARDIOGRAM
16.4 ELECTROMYOGRAPHY
16.5 CHEST X-RAY AND CT SCAN OF THE CHEST
16.6 LUNG FUNCTION TESTS
16.7 SWALLOWING STUDY
16.8 MYOSITIS SPECIFIC ANTIBODY PANEL BLOOD TEST
16.9 GENETIC TESTING
16.1 OTHERS
17 GLOBAL MYOSITIS TREATMENT MARKET, BY DRUG TYPE
17.1 OVERVIEW
17.2 BRANDED
17.2.1 WYSOLONE
17.2.2 AZATHIOPRINE
17.2.3 METHOTREXATE
17.2.4 DELTASONE
17.2.5 ACTEMRA
17.2.6 METICORTEN
17.2.7 SANDIMMUNE
17.2.8 NEORAL
17.2.9 PROGRAF
17.2.10 ADVAGRAF
17.2.11 OTHERS
17.3 GENERIC
18 GLOBAL MYOSITIS TREATMENT MARKET, BY AGE
18.1 OVERVIEW
18.2 ADULT
18.3 GERIATRICS
19 GLOBAL MYOSITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
19.1 OVERVIEW
19.2 ORAL
19.3 INJECTABLE
19.4 OTHERS
20 GLOBAL MYOSITIS TREATMENT MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.3 SPECIALTY CLINICS
20.4 HOME HEALTHCARE
20.5 THERAPY CENTERS
20.6 OTHERS
21 GLOBAL MYOSITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 HOSPITAL PHARMACIES
21.3 ONLINE PHARMACIES
21.4 RETAIL PHARMACIES
21.5 OTHERS
22 GLOBAL MYOSITIS TREATMENT MARKET , BY REGION
22.1 GLOBAL MYOSITIS TREATMENT MARKET , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.2 NORTH AMERICA
22.2.1 U.S.
22.2.2 CANADA
22.2.3 MEXICO
22.3 EUROPE
22.3.1 GERMANY
22.3.2 U.K.
22.3.3 ITALY
22.3.4 FRANCE
22.3.5 SPAIN
22.3.6 RUSSIA
22.3.7 SWITZERLAND
22.3.8 TURKEY
22.3.9 BELGIUM
22.3.10 NETHERLANDS
22.3.11 DENMARK
22.3.12 SWEDEN
22.3.13 POLAND
22.3.14 NORWAY
22.3.15 FINLAND
22.3.16 REST OF EUROPE
22.4 ASIA-PACIFIC
22.4.1 JAPAN
22.4.2 CHINA
22.4.3 SOUTH KOREA
22.4.4 INDIA
22.4.5 SINGAPORE
22.4.6 THAILAND
22.4.7 INDONESIA
22.4.8 MALAYSIA
22.4.9 PHILIPPINES
22.4.10 AUSTRALIA
22.4.11 NEW ZEALAND
22.4.12 VIETNAM
22.4.13 TAIWAN
22.4.14 REST OF ASIA-PACIFIC
22.5 SOUTH AMERICA
22.5.1 BRAZIL
22.5.2 ARGENTINA
22.5.3 REST OF SOUTH AMERICA
22.6 MIDDLE EAST AND AFRICA
22.6.1 SOUTH AFRICA
22.6.2 EGYPT
22.6.3 BAHRAIN
22.6.4 UNITED ARAB EMIRATES
22.6.5 KUWAIT
22.6.6 OMAN
22.6.7 QATAR
22.6.8 SAUDI ARABIA
22.6.9 REST OF MEA
22.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL MYOSITIS TREATMENT MARKET , SWOT AND DBMR ANALYSIS
24 GLOBAL MYOSITIS TREATMENT MARKET , COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.3 COMPANY SHARE ANALYSIS: EUROPE
24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.5 MERGERS & ACQUISITIONS
24.6 NEW PRODUCT DEVELOPMENT & APPROVALS
24.7 EXPANSIONS
24.8 REGULATORY CHANGES
24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL MYOSITIS TREATMENT MARKET , COMPANY PROFILE
25.1 CSL
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 MERCK & CO.
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 PFIZER INC
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 CORBUS PHARMACEUTICALS HOLDINGS, INC.
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 NOVARTIS
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 ADMA BIOLOGICS, INC.
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 GSK PLC.
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 ACCORD HEALTHCARE
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 APOTEX INC
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 SANDOZ INTERNATIONAL GMBH
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 DR. REDDY’S LABORATORIES LTD.
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 TEVA PHARMACEUTICALS USA, INC.
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 SUN PHARMACEUTICAL INDUSTRIES LTD.
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 HIKMA PHARMACEUTICALS PLC
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 ANANT PHARMACEUTICALS
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 AUROBINDO PHARMA USA
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 LUPIN PHARMACEUTICALS, INC
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 ABBVIE INC
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 ZENTIVA
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.2 ASTELLAS PHARMA INC.
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
